Tumors Promote Altered Maturation and Early Apoptosis of Monocyte-Derived Dendritic Cells

Sylvia M. Kiertscher, Jie Luo, Steven M. Dubinett and Michael D. Roth

J Immunol 2000; 164:1269-1276; doi: 10.4049/jimmunol.164.3.1269
http://www.jimmunol.org/content/164/3/1269

Why The JI?

• Rapid Reviews! 30 days* from submission to initial decision
• No Triage! Every submission reviewed by practicing scientists
• Speedy Publication! 4 weeks from acceptance to publication

References This article cites 50 articles, 26 of which you can access for free at:
http://www.jimmunol.org/content/164/3/1269.full#ref-list-1

Subscription Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

Permissions Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Monocyte-Derived Dendritic Cells

Tumors Promote Altered Maturation and Early Apoptosis of Monocyte-Derived Dendritic Cells

Sylvia M. Kiertscher, Jie Luo, Steven M. Dubinett, and Michael D. Roth

Tumors produce a number of immunosuppressive factors that block the maturation of CD34+ stem cells into dendritic cells (DC). We hypothesized that tumors might also interfere with the maturation and/or function of human monocyte-derived DC. In contrast to stem cells, we found that CD14+ cells responded to tumor culture supernatant (TSN) by increasing expression of APC surface markers, up-regulating nuclear translocation of RelB, and developing allostimulatory activity. Although displaying these characteristics of mature DC, TSN-exposed DC lacked the capacity to produce IL-12, did not acquire full allostimulatory activity, and rapidly underwent apoptosis. The effects of TSN appeared to be specific for maturing DC, and were not reversed by Abs against known DC regulatory factors including IL-10, vascular endothelial growth factor, TGF-β, or PGE2. Supernatants collected from nonmalignant cell sources had no effect on DC maturation. The altered maturation and early apoptosis of monocyte-derived DC may represent another mechanism by which tumors evade immune detection. The Journal of Immunology, 2000, 164: 1269–1276.

Materials and Methods

Cell lines and reagents

The A549 non-small cell lung carcinoma, the IMR90 lung fibroblast, the MCF-7 breast carcinoma (all from American Type Culture Collection, Manassas, VA), the A427 lung adenocarcinoma (obtained from Dr. J. A. Radoshevich, Northwestern University, Chicago, IL), the R11 renal cell carcinoma (generous gift of Dr. A. Beldegrun, UCLA School of Medicine, Los Angeles, CA), and the UCLA-SOM-M14 (M14) melanoma cell lines were maintained in complete medium composed of RPMI 1640 (Invitrogen, San Diego, CA) supplemented with 10% heat-inactivated human AB serum (Gemini Bioproducts, Calabasas, CA), penicillin-streptomycin, and 1% nonessential amino acids (Gibco, Gaithersburg, MD). Cell lines were grown to near confluence (70–90%) and then harvested for the experiments. All other cell lines were obtained from the American Type Culture Collection and were cultured according to the supplier’s recommendations.

Preparation of TSN and TSN-exposed DC

TSN were prepared by seeding 25-cm² flasks with 1 × 10⁶ tumor cells in 10 ml of complete medium. The culture supernatants were collected after 24 h, centrifuged to remove cells, and stored at −80°C. DC were generated from the adherent fraction of peripheral blood, as previously described (17, 19). Briefly, PBMC were allowed to adhere for 2 h in culture flasks, non-adherent cells were gently removed, and the remaining cells were cultured

Copyright © 2000 by The American Association of Immunologists

Received for publication July 8, 1999. Accepted for publication November 18, 1999.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Division of Pulmonary and Critical Care Medicine and 2 Jonsson Comprehensive Cancer Center, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095; and 3 West Los Angeles Veterans Affairs Medical Center, Los Angeles, CA 90073

2 Address correspondence and reprint requests to Dr. Sylvia Kiertscher, UCLA School of Medicine, 10833 Le Conte Ave., CHS 11-220, Los Angeles, CA 90095-1690. E-mail address: skierscher@mednet.ucla.edu

3 Abbreviations used in this paper: DC, dendritic cells; LFL, linear fluorescence intensity; TSN, tumor supernatant; VEGF, vascular endothelial growth factor; CD40L, CD40 ligand.
in complete medium supplemented with 800 U/ml (71 ng/ml) GM-CSF and 500 U/ml (63 ng/ml) IL-4. The effects of TSN on DC maturation were examined by replacing 0–50% of the culture medium with TSN at the initiation of culture. In some experiments, the TSN was washed out after 24 h and replaced with fresh medium and cytokines. In other experiments, IL-12 was added in addition to GM-CSF and IL-4. After either 4 or 7 days in culture, all free or loosely adherent cells were collected by vigorous rinsing. DC were further purified by negative depletion using an Ab mixture in conjunction with anti-mouse Ig-conjugated immunomagnetic beads (17) (Dynal, Lake Success, NY). To examine the effects of TSN on mature DC, control DC were collected on day 7 and cultured for 40 h in fresh medium and cytokines, in the presence or absence of 50% TSN.

**DC phenotype and function**

DC were analyzed by three-color FACS analysis using a FACScan II flow cytometer and CellQuest software (Becton Dickinson) with 5,000–10,000 events acquired for each sample. Control and TSN-DC collected on days 4 and 7 were assayed for their ability to stimulate allogeneic T cells in an MLR. Purified DC were cocultured with \( \times 10^5 \) CD3+ T cells from an unrelated donor at ratios of 1:20, 1:50, and 1:100 DC:T cells. Allogeneic CD3+ T cells were prepared by negative depletion of nonadherent PBMC with an Ab mixture and immunomagnetic beads. The assays were performed in triplicate in round-bottom 96-well plates. No TSN was present during the MLR assay. After 5 days of coculture, the wells were pulsed for 18 h with 1 μCi/well tritiated thymidine (Amersham, Arlington Heights, IL). Apoptosis was assessed by uptake of FITC-dextran (20). DC were incubated for 1 h at 37°C in the presence of 1 mg/ml FITC-dextran (40,000 m.w.; Molecular Probes, Eugene, OR). Control cells were incubated on ice for 1 h. After extensive washing, the cells were analyzed by single-color FACS analysis. Cytokine production was assessed by stimulating purified DC (3 \( \times 10^5 \) cells/ml) for 24 h with CD40L (1 μg/ml) in the presence or absence of TNF-α (1000 U/ml) (21). DC supernatants were then analyzed by ELISA for IL-12 p70 (Genzyme, Cambridge, MA), PGE2 (Ab pairs; Cayman Chemical, Ann Arbor, MI), and IL-10 (Ab pairs; PharMingen).

**Western blot analysis of RelB**

DC collected on days 4 and 7 were pelleted, washed, and lysed (4°C, 15 min; 10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.1 mM EDTA, 1 mM DTT, 0.5 mM PMSF, and 0.6% Nonidet P-40). After centrifugation (6000 rpm, 10 min), the supernatant (cytoplasmic protein) was collected. The pelleted nuclei were mixed with buffer (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1.5 mM MgCl2, 0.1 mM EDTA, 0.1 mM EGTA, 0.5 mM DTT, 0.5 mM PMSF, 25% glycerol) and kept on ice with occasional vortex mixing. After centrifugation (13,000 rpm, 10 min), the supernatant (nuclear protein) was collected. For Western blotting, 20 μg protein samples were resolved on a 12% SDS-PAGE gel and transferred to Hybond-ECL membranes (Amersham Life Sciences, Arlington Heights, IL). The Western analysis was performed using anti-RelB and anti-actin (both from Santa Cruz Biotechnology, Santa Cruz, CA) and the Amersham Life Science analysis was performed using anti-RelB and anti-actin (both from Santa Cruz Biotechnology, Santa Cruz, CA) and the Amersham Life Science analysis was performed using anti-RelB and anti-actin (both from Santa Cruz Biotechnology, Santa Cruz, CA) and the Amersham Life Science analysis was performed using anti-RelB and anti-actin (both from Santa Cruz Biotechnology, Santa Cruz, CA).

**Apoptosis**

DC were assessed for apoptosis by two methods. The exposure of phosphatidylserine residues on the cell surface was measured using annexin-V FITC, with dead cells identified with propidium iodide (Bender Medsystems kit, distributed by Biosource International, Camarillo, CA). These results were confirmed using a FACS-based TUNEL assay (APO-BrdU kit; PharMingen). For both of these assays, 10,000 events were collected on the FACSScan II cytometer and analyzed with CellQuest software.

**Results**

To evaluate effects of the tumor environment on the maturation of monocyte-derived DC, adherent PBMC were cultured with GM-CSF and IL-4 in the presence or absence of TSN from the A549 lung cancer cell line. Maturing DC were assessed at days 4 and 7 of culture for expression of APC surface molecules by FACS, T cell stimulatory activity in an allogeneic MLC, endocytic capacity, translocation of RelB to the nucleus, and the ability to produce cytokines in response to stimulation by CD40L.

**DC phenotype and function**

As shown in Fig. 1, exposure of maturing DC to TSN enhanced their early expression of cell surface molecules associated in Ag presentation, including CD80 (B7-1), CD86 (B7-2), CD40, and HLA-DR. A marker expressed on both immature and mature DC, CD11c, was reduced in cells cultured with TSN, while the same cells expressed higher than control levels of CD83, a marker of more mature DC. Between days 4 and 7, the expression of APC markers, as measured by mean linear fluorescence intensity (LFI), was maintained (CD80, 331 vs 313 LFI; CD83, 59 vs 63 LFI; CD11c, 5995 vs 5913 LFI) or continued to increase (CD86, 2204 vs 2392 LFI; CD40, 494 vs 576 LFI; HLA-DR, 3365 vs 4734 LFI) on control DC. In contrast, APC marker expression remained relatively constant (CD86, 6637 vs 6108 LFI; HLA-DR, 4752 vs 4990 LFI) or significantly decreased (CD80, 2137 vs 1290 LFI; CD40, 1101 vs 715 LFI; CD83, 433 vs 102 LFI; CD11c, 2642 vs 910 LFI) on DC grown in the presence of TSN. To evaluate the difference between tumor-related and non-tumor-related effects of cell culture supernatants, adherent PBMC also were cultured with GM-CSF and IL-4 in the presence of supernatants from the non-malignant lung fibroblast cell line IMR90, or from cultured allogeneic PBMC. These supernatants had no effect on maturing DC phenotype (results not shown).

A number of tumor-derived factors with the capacity to alter the differentiation of monocyte-derived DC, VCAM-1 (14), or CD44+ precursors (IL-10, PGE2) (22–24) are produced by A549 (25–27). The role of these factors in TSN-induced phenotypic changes was evaluated by adding neutralizing mAbs to the culture medium during DC maturation. Neutralization of these cytokines...
Neutralizing Abs to VEGF, TGF-β, PGE₂, and IL-10 do not block the effects of TSN on DC phenotype and apoptosis

Table I. Neutralizing Abs to VEGF, TGF-β, PGE₂, and IL-10 do not block the effects of TSN on DC phenotype and apoptosis

<table>
<thead>
<tr>
<th>Expt. 1</th>
<th>Phenotype</th>
<th>Apoptosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B7-2</td>
<td>HLA-DR</td>
</tr>
<tr>
<td>No TSN</td>
<td>2502.6</td>
<td>1539.8</td>
</tr>
<tr>
<td>TSN</td>
<td>3567.9</td>
<td>1308.0</td>
</tr>
<tr>
<td>TSN + anti-VEGF</td>
<td>4120.2</td>
<td>1557.4</td>
</tr>
<tr>
<td>TSN + anti-TGF-β</td>
<td>4815.5</td>
<td>1855.6</td>
</tr>
<tr>
<td>TSN + anti-PGE₂ and α-IL-10</td>
<td>6637.5</td>
<td>2609.8</td>
</tr>
</tbody>
</table>

*Cells were collected after 4 days of culture in GM-CSF and IL-4 in the presence or absence of 50% TSN, with neutralizing Abs to the noted factors. Neutralizing Abs were used at 5–10 μg/ml. APC cell surface molecule expression was assessed by staining with mAbs. Numerical values denote the mean fluorescence intensities. Apoptosis was measured by annexin binding and is expressed as percentage of positive cells.

Nuclear translocation of RelB

Translocation of RelB to the nucleus, an event associated with DC maturation (28, 29), was assessed by resolving nuclear and cytoplasmic proteins on SDS-PAGE gels, followed by Western blotting. Consistent with the increased allostimulatory activity of the TSN-DC on day 4, there were high levels of RelB protein in both the cytoplasm and nucleus, while only minimal levels were observed in control DC on day 4 (Fig. 4). However, by day 7, the levels of RelB were greatly reduced in TSN-DC, while control DC showed enhanced nuclear translocation of RelB, consistent with their slower maturation.

Cytokine production by DC

The ability of DC to produce IL-12 when stimulated through CD40 is important for the generation of protective immunity. Stimulation with the combination of CD40L and IFN-γ resulted in production of IL-12 p70 (the bioactive form of IL-12) by the control cells, but not by DC exposed to TSN (Table II). The DC exposed to TSN...
also were impaired in their ability to produce IL-10, but did respond to stimulation by producing PGE2 at levels equal to or greater than that produced by control DC.

**TSN induced early DC apoptosis**

Viable cell yield was reduced in DC cultures containing TSN (70 ± 1.4% of control, n = 4), leading us to investigate the effect of TSN on DC apoptosis. As shown in Fig. 5, the percentages of both apoptotic (51.4 vs 6.7%) and dead (24 vs 12.5%) cells were higher in the day 4 TSN-DC. It is unlikely that the apoptosis-inducing effect of TSN was due to changes in cell culture pH or nutrient deprivation, since as little as 1% TSN produced substantial increases in annexin binding (Fig. 6, left panel). In addition, supernatants from neither allogeneic PBMC nor the nonmalignant lung fibroblast cell line IMR90 increased DC apoptosis. The effects of TSN on DC apoptosis were not neutralized by Abs against IL-10, VEGF, TGF-β, or PGE2 (Table I).

In contrast to the effects on DC precursors, TSN did not induce apoptosis in resting or activated T cells. TSN was added at a 50% concentration to CD3+ cells alone, or to CD3+ cells undergoing activation with IL-2 or immobilized anti-CD3/CD28. Although the presence of IL-2 or anti-CD3/CD28 both induced a certain level of apoptosis (11.6% and 49.4%, respectively), no enhancement of this level was seen with the addition of TSN (IL-2 TSN, 12.3%; anti-CD3/CD28 TSN, 50.6%). Taken together, these data suggest that the apoptosis-inducing effects of TSN are specific for maturing DC.

**TSN from a variety of tumor types induced DC apoptosis**

TSN obtained from an additional lung cancer (A427), a breast cancer (MCF-7), a renal cell carcinoma (R11), and a melanoma (M14) cell line also were evaluated for their effect on DC maturation. At day 4 of culture, TSN from all of the tumor cell lines induced similar levels of apoptosis in DC (Fig. 6, right panel). None of the day 6 TSN-treated DC were capable of producing IL-12 at the same levels as the control cells following stimulation with CD40L and IFN-γ (A427 and R11, <2 pg/ml; M14, 9 pg/ml), although MCF-7 TSN-treated DC did produce moderate amounts (630 pg/ml). In addition, TSN from all of the tumors enhanced expression of characteristic cell surface molecules (Fig. 7), and resulted in cells with enhanced allostimulatory activity at day 4 (data not shown), suggesting that the immunomodulating effects mediated by A549 are shared by a variety of tumor types.

### Table II. DC exposed to TSN have a decreased ability to produce IL-12 and IL-10

<table>
<thead>
<tr>
<th>Condition</th>
<th>IL-12 p70 (pg/ml)</th>
<th>IL-10 (pg/ml)</th>
<th>PGE2 (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control + TSN</td>
<td>Control + TSN</td>
<td>Control + TSN</td>
</tr>
<tr>
<td>Day 4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unstimulated</td>
<td>&lt;2</td>
<td>10</td>
<td>480</td>
</tr>
<tr>
<td>CD40L</td>
<td>&lt;2</td>
<td>32</td>
<td>750</td>
</tr>
<tr>
<td>CD40L + IFN-γ</td>
<td>114</td>
<td>107</td>
<td>1220</td>
</tr>
<tr>
<td>Day 6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unstimulated</td>
<td>&lt;2</td>
<td>13</td>
<td>600</td>
</tr>
<tr>
<td>CD40L</td>
<td>23</td>
<td>442</td>
<td>920</td>
</tr>
<tr>
<td>CD40L + IFN-γ</td>
<td>975</td>
<td>369</td>
<td>650</td>
</tr>
</tbody>
</table>

*Control and TSN-DC were collected and purified on days 4 and 6 of culture. Purified DC (3 x 10^5 cells/ml) were stimulated for 24 h with CD40L (1 μg/ml) with or without IFN-γ (1000 U/ml). ELISA assays for IL-12 p70, IL-10, and PGE2 were performed on the supernatants. The data shown are representative of two similar experiments.
TSN affected developing, but not mature DC

DC precursors exposed to TSN for only the first 24 h of culture demonstrated altered maturation and apoptosis similar to that observed with cells continuously exposed to TSN (Fig. 8). In contrast, DC precursors that were allowed to mature for 7 days in GM-CSF and IL-4 before exposure to TSN for 48 h resembled control DC (Fig. 9). These cells did not up-regulate HLA-DR, CD80, or CD86, indicating that TSN does not act as a final maturation factor like LPS, CD40L, and monocyte-conditioned medium (30–35). Therefore, the effects of TSN appear to be maturation dependent, acting only on DC precursors and not mature DC.

IL-12 did not protect against TSN-induced apoptosis of DC

It has been demonstrated that IL-12 protects DC from the induction of apoptosis by anti-Fas Ab in vitro (36), and is involved in the survival-enhancing effect of CD40 ligation in vivo (37). Coupled with the lack of production of IL-12 by the TSN-exposed DC, it is possible that exogenous IL-12 could have a similar effect on the induction of apoptosis by TSN. We added a range of IL-12 concentrations (0.2–100 ng/ml) to adherent PBMC at the initiation of DC culture. As shown in Fig. 10, addition of IL-12 did not decrease the level of apoptosis in the TSN-DC. No change was observed in the expression of APC cell surface molecules (data not shown).
Factors that prevent DC maturation from CD34+ precursors exposed to TSN demonstrated increased levels of both cytoplasmic and nuclear RelB. This increase coincided with the rapid up-regulation of APC cell surface molecules and activity, but levels diminished substantially by day 7, corresponding to a reduction in functional activity. In contrast, control DC reached their maximal levels of RelB expression at day 7, corresponding to their slow, progressive development of APC cell surface molecule expression and allostimulatory activity. Despite their differences in response to TSN, the expression and translocation of RelB appear to coincide with the acquisition of APC function in both monocyte and CD34+-derived DC.

The number of DC infiltrating tumor sites has been correlated with prognosis and survival (38). Many tumors have reduced numbers of DC, and those DC that are present have low functional activity (8–13). Our data suggest that tumor-derived factors induce monocyte-derived DC to undergo apoptosis early during their maturation. Furthermore, the cells that remain viable at day 7 have reduced allostimulatory activity and do not produce IL-12, but rather produce high levels of PGE2. The functional consequences of these cytokine changes may be quite important because a reduction in IL-12 levels may prevent stimulation of Th1 T cell responses, and skew responding T cells toward a Th2 response (39, 40). In addition, IL-12 has been reported to act as an antiapoptotic factor for DC (36, 37), and lack of production by DC may contribute to early cell death. However, in our hands, the addition of exogenous IL-12 was unable to prevent TSN-induced DC apoptosis. Although TSN-exposed DC do not produce IL-10, enhanced levels of PGE2 in the lung tumor microenvironment have been shown to promote IL-10 production by T cells and tumor cells (41). In the absence of IL-12 production by the DC, increased levels of IL-10 may lead to the development of Ag-specific anergy (42, 43). Other investigators have compared the cytokine profiles of progressing and regressing metastases obtained from the same patient, and have reported that progressing metastases express high levels of IL-10, while regressing metastases express IL-1, IFN-γ, and IL-12. DC from progressing metastases induced anergy in CD4+ T cells, which could be reversed by the addition of exogenous IL-12 or IL-2 (13).

Apoptosis is a tightly regulated process that occurs normally during cellular activation, maturation, and senescence. We observed DC apoptosis late in the maturation of control DC, and a similar outcome has been reported for activated T cells (44) and for DC induced to mature by bacterial engulfment (28). Apoptosis may serve an important role by removing cells after they have served their functional purpose and allowing the immune system to return to homeostasis. Our data suggest that tumor cells may take advantage of this process by promoting a premature apoptosis that destroys DC before they can effectively interact with T cells. Certain factors and events have been shown to promote the survival of mature activated DC, including exogenous IL-12, TRANCE, and CD40L (36, 45, 46), as well as survival signals provided by Ag-specific interactions with T cells (47). It is unclear whether these substances have the same antiapoptotic effect on developing DC, and an evaluation of their ability to counteract the effects of TSN will be the focus of further study.

The use of ex vivo generated DC to overcome the APC deficiencies in cancer patients is the rationale behind recent clinical studies. Methods have been developed to pulse DC with tumor Ags before readministration to the patient, with the hope that an increase in the number of functional tumor Ag-presenting DC will generate specific antitumor responses and immunity. Deleterious

**FIGURE 10.** Exogenous IL-12 did not prevent TSN-induced DC apoptosis. Cells were cultured for 4 days in GM-CSF and IL-4 in the presence or absence of 50% TSN, with or without 0.2–100 ng/ml IL-12. The percentages of apoptotic and dead cells were determined by annexin binding and propidium iodide staining. The results shown are representative of three similar experiments.

**Discussion**

Circulating and tumor-infiltrating DC collected from cancer patients appear to be phenotypically and functionally defective (10–12). A variety of tumor-derived cytokines, including VEGF, IL-6, and M-CSF, have been shown to alter the maturation of DC from CD34+ precursors in vitro (14, 15). Instead of producing functionally active DC, these factors promote the development of monocyte-like cells with little APC activity. These TSN effects led us to hypothesize that factors present in the tumor environment might similarly interfere with the maturation and/or function of monocyte-derived DC. Although we confirmed this hypothesis, the mechanism by which TSN acts on monocytic DC precursors appears to be quite unique. In contrast to its effects on CD34+ precursors, we found that TSN induced an early maturation of monocyte-derived DC, as characterized by rapid up-regulation of CD80, CD86, and HLA-DR, translocation of RelB to the nucleus, and early development of allostimulatory activity. However, this maturation process was ultimately defective, resulting in DC that failed to produce IL-12 after stimulation by CD40L, exhibited reduced endocytic activity, failed to develop full allostimulatory activity, and underwent rapid apoptosis.

DC maturation is a coordinated process involving up-regulation of cell surface molecules, cytokine production, and functional activity (28). DC that fail to develop properly may be unable to stimulate Ag-specific T cells, or may promote the development of T cell anergy (13). It appears that TSN disrupts the maturation process by inducing monocyte DC precursors to develop some, but not all, of the characteristic properties of DC. The resulting DC, while appearing phenotypically mature, have functional defects that impact on their ability to stimulate specific T cell responses. In addition, TSN-exposed DC undergo apoptosis at an early time point, reducing the window of time during which they might interact with T cells in vivo. These effects of TSN on monocyte DC precursors are clearly different from those reported for CD34+ DC precursors. CD34+ cells exposed to TSN during DC maturation do not up-regulate CD80 and CD86 expression, develop only minimal HLA-DR expression, and never acquire significant APC activity (14, 15). The differential effects of TSN on maturation of DC from CD34+ and monocyte precursors suggest two distinct pathways by which tumors might suppress immune recognition.

Activation of the NF-xB/RelB family and translocation of RelB from the cytoplasm to the nucleus are associated with the maturation of DC (28) and development of Ag-presenting activity (29). Factors that prevent DC maturation from CD34+ precursors also inhibit NF-xB activity and decrease RelB and c-Rel activation, consistent with the failure of the cells to develop APC phenotype or functional activity (16). Monocyte DC precursors exposed to TSN demonstrated increased levels of both cytoplasmic and nuclear RelB. This increase coincided with the rapid up-regulation of APC cell surface molecules and activity, but levels diminished substantially by day 7, corresponding to a reduction in functional activity. In contrast, control DC reached their maximal levels of RelB expression at day 7, corresponding to their slow, progressive development of APC cell surface molecule expression and allostimulatory activity. Despite their differences in response to TSN, the expression and translocation of RelB appear to coincide with the acquisition of APC function in both monocyte and CD34+-derived DC.

The number of DC infiltrating tumor sites has been correlated with prognosis and survival (38). Many tumors have reduced numbers of DC, and those DC that are present have low functional activity (8–13). Our data suggest that tumor-derived factors induce monocyte-derived DC to undergo apoptosis early during their maturation. Furthermore, the cells that remain viable at day 7 have reduced allostimulatory activity and do not produce IL-12, but rather produce high levels of PGE2. The functional consequences of these cytokine changes may be quite important because a reduction in IL-12 levels may prevent stimulation of Th1 T cell responses, and skew responding T cells toward a Th2 response (39, 40). In addition, IL-12 has been reported to act as an antiapoptotic factor for DC (36, 37), and lack of production by DC may contribute to early cell death. However, in our hands, the addition of exogenous IL-12 was unable to prevent TSN-induced DC apoptosis. Although TSN-exposed DC do not produce IL-10, enhanced levels of PGE2 in the lung tumor microenvironment have been shown to promote IL-10 production by T cells and tumor cells (41). In the absence of IL-12 production by the DC, increased levels of IL-10 may lead to the development of Ag-specific anergy (42, 43). Other investigators have compared the cytokine profiles of progressing and regressing metastases obtained from the same patient, and have reported that progressing metastases express high levels of IL-10, while regressing metastases express IL-1, IFN-γ, and IL-12. DC from progressing metastases induced anergy in CD4+ T cells, which could be reversed by the addition of exogenous IL-12 or IL-2 (13).

Apoptosis is a tightly regulated process that occurs normally during cellular activation, maturation, and senescence. We observed DC apoptosis late in the maturation of control DC, and a similar outcome has been reported for activated T cells (44) and for DC induced to mature by bacterial engulfment (28). Apoptosis may serve an important role by removing cells after they have served their functional purpose and allowing the immune system to return to homeostasis. Our data suggest that tumor cells may take advantage of this process by promoting a premature apoptosis that destroys DC before they can effectively interact with T cells. Certain factors and events have been shown to promote the survival of mature activated DC, including exogenous IL-12, TRANCE, and CD40L (36, 45, 46), as well as survival signals provided by Ag-specific interactions with T cells (47). It is unclear whether these substances have the same antiapoptotic effect on developing DC, and an evaluation of their ability to counteract the effects of TSN will be the focus of further study.

The use of ex vivo generated DC to overcome the APC deficiencies in cancer patients is the rationale behind recent clinical studies. Methods have been developed to pulse DC with tumor Ags before readministration to the patient, with the hope that an increase in the number of functional tumor Ag-presenting DC will generate specific antitumor responses and immunity. Deleterious
effects of tumors on readministered DC could have serious consequences for the efficacy of these treatments. Encouragingly, our results suggest that DC reach a maturation point at which TSN has little or no effect. Although early exposure results in dysfunctional maturation and apoptosis of DC, addition of TSN to day 7 DC did not induce phenotypic changes or apoptosis. Reports that DC prepared ex vivo from monocyte precursors were able to stimulate antitumor responses in patients are consistent with this observation (48–50).

In summary, tumors have at least two mechanisms by which they can alter DC maturation and function. The first, mediated by tumor-derived VEGF, M-CSF, and IL-6, affects CD34+ precursors by promoting the generation of immature DC that lack the cell surface phenotype and T cell stimulatory activity characteristic of mature, functional DC (14, 15). The second pathway, demonstrated in this study, is the ability of soluble tumor-derived factors to promote dysfunctional maturation and early apoptosis of DC developing from monocyte precursors. This ability was observed even at low TSN concentrations, and was common to a variety of tumor types. The cytokines IL-10, TGF-β, and VEGF, which have been shown to have immunomodulatory effects on CD34+ and/or CD14+ DC precursors, are produced in picogram quantities by A549. However, the addition of neutralizing Abs to these factors did not block TSN-induced changes in phenotype and apoptosis. The factor(s) and mechanism responsible for these effects of TSN remain to be determined and are the focus of ongoing study. By acting on both CD34+ and monocyte DC precursors, tumors might effectively evade immune recognition and prevent the establishment of an antitumor T cell response.

Acknowledgments

We thank Li Zhu for his assistance with the ELISA assays, and Marc Mendenhall for her technical support. We thank Li Zhu for his assistance with the ELISA assays, and Marcy Mendenhall for her technical support. We thank Li Zhu for his assistance with the ELISA assays, and Marcy Mendenhall for her technical support. We thank Li Zhu for his assistance with the ELISA assays, and Marcy Mendenhall for her technical support. We thank Li Zhu for his assistance with the ELISA assays, and Marcy Mendenhall for her technical support.

References


